Literature DB >> 15367590

Human immunodeficiency virus type 1 gag-specific mucosal immunity after oral immunization with papillomavirus pseudoviruses encoding gag.

Hongtao Zhang1, Raja Fayad, Xilin Wang, Daniel Quinn, Liang Qiao.   

Abstract

Mucosal surfaces are the primary portals for human immunodeficiency virus (HIV) transmission. Because systemic immunization, in general, does not induce effective mucosal immune responses, a mucosal HIV vaccine is urgently needed. For this study, we developed papillomavirus pseudoviruses that express HIV-1 Gag. The pseudoviruses are synthetic, nonreplicating viruses, yet they can produce antigens for a long time in the immune system. Here we show that oral immunization of mice by the use of papillomavirus pseudoviruses encoding Gag generated mucosal and systemic Gag-specific cytotoxic T lymphocytes that effectively lysed Gag-expressing target cells. Furthermore, the pseudoviruses generated Gag-specific gamma interferon-producing T cells and serum immunoglobulin G (IgG) and mucosal IgA. In contrast, oral immunization with plasmid DNA encoding HIV-1 Gag did not induce specific immune responses. Importantly, oral immunization with the pseudoviruses induced Gag-specific memory cytotoxic T lymphocytes and protected mice against a rectal mucosal challenge with a recombinant vaccinia virus expressing HIV-1 Gag. Thus, papillomavirus pseudoviruses encoding Gag are a promising mucosal vaccine against AIDS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15367590      PMCID: PMC516374          DOI: 10.1128/JVI.78.19.10249-10257.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  83 in total

1.  Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection.

Authors:  L Musey; J Hughes; T Schacker; T Shea; L Corey; M J McElrath
Journal:  N Engl J Med       Date:  1997-10-30       Impact factor: 91.245

2.  Carboxyl terminus of bovine papillomavirus type-1 L1 protein is not required for capsid formation.

Authors:  J Paintsil; M Müller; M Picken; L Gissmann; J Zhou
Journal:  Virology       Date:  1996-09-01       Impact factor: 3.616

3.  Chimeric papillomavirus-like particles.

Authors:  M Müller; J Zhou; T D Reed; C Rittmüller; A Burger; J Gabelsberger; J Braspenning; L Gissmann
Journal:  Virology       Date:  1997-07-21       Impact factor: 3.616

4.  Cell mediated immunity induced in mice by HPV 16 L1 virus-like particles.

Authors:  C Dupuy; D Buzoni-Gatel; A Touze; P Le Cann; D Bout; P Coursaget
Journal:  Microb Pathog       Date:  1997-04       Impact factor: 3.738

5.  Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice.

Authors:  D Nardelli-Haefliger; R B Roden; J Benyacoub; R Sahli; J P Kraehenbuhl; J T Schiller; P Lachat; A Potts; P De Grandi
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

6.  Oral immunization with simian immunodeficiency virus p55gag and cholera toxin elicits both mucosal IgA and systemic IgG immune responses in nonhuman primates.

Authors:  M Kubota; C J Miller; K Imaoka; S Kawabata; K Fujihashi; J R McGhee; H Kiyono
Journal:  J Immunol       Date:  1997-06-01       Impact factor: 5.422

Review 7.  Papillomavirus-like particles and HPV vaccine development.

Authors:  J T Schiller; D R Lowy
Journal:  Semin Cancer Biol       Date:  1996-12       Impact factor: 15.707

8.  Cytotoxic T lymphocytes recognize structurally diverse, clade-specific and cross-reactive peptides in human immunodeficiency virus type-1 gag through HLA-B53.

Authors:  L Dorrell; B E Willcox; E Y Jones; G Gillespie; H Njai; S Sabally; A Jaye; K DeGleria; T Rostron; E Lepin; A McMichael; H Whittle; S Rowland-Jones
Journal:  Eur J Immunol       Date:  2001-06       Impact factor: 5.532

9.  Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro.

Authors:  M P Rudolf; S C Fausch; D M Da Silva; W M Kast
Journal:  J Immunol       Date:  2001-05-15       Impact factor: 5.422

Review 10.  Virologic and immunologic events in primary HIV infection.

Authors:  G Pantaleo; C Graziosi; A S Fauci
Journal:  Springer Semin Immunopathol       Date:  1997
View more
  7 in total

Review 1.  Biological gene delivery vehicles: beyond viral vectors.

Authors:  Yiqi Seow; Matthew J Wood
Journal:  Mol Ther       Date:  2009-03-10       Impact factor: 11.454

2.  Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal external region of HIV-1 gp41 induced mucosal and systemic antibodies.

Authors:  Yougang Zhai; Zhenyu Zhong; Mohammadreza Zariffard; Gregory T Spear; Liang Qiao
Journal:  Vaccine       Date:  2013-09-19       Impact factor: 3.641

3.  Targeting the vaginal mucosa with human papillomavirus pseudovirion vaccines delivering simian immunodeficiency virus DNA.

Authors:  Shari N Gordon; Rhonda C Kines; Galyna Kutsyna; Zhong-Min Ma; Anna Hryniewicz; Jeffery N Roberts; Claudio Fenizia; Rachmat Hidajat; Egidio Brocca-Cofano; Nicolas Cuburu; Christopher B Buck; Marcelino L Bernardo; Marjorie Robert-Guroff; Christopher J Miller; Barney S Graham; Douglas R Lowy; John T Schiller; Genoveffa Franchini
Journal:  J Immunol       Date:  2011-12-14       Impact factor: 5.422

4.  Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination.

Authors:  B S Graham; R C Kines; K S Corbett; J Nicewonger; T R Johnson; M Chen; D LaVigne; J N Roberts; N Cuburu; J T Schiller; C B Buck
Journal:  Mucosal Immunol       Date:  2010-06-16       Impact factor: 7.313

5.  Efficient delivery of DNA vaccines using human papillomavirus pseudovirions.

Authors:  S Peng; A Monie; T H Kang; C-F Hung; R Roden; T-C Wu
Journal:  Gene Ther       Date:  2010-07-29       Impact factor: 5.250

6.  Papilloma-pseudovirus eradicates intestinal tumours and triples the lifespan of ApcMin/+ mice.

Authors:  Zhenyu Zhong; Yougang Zhai; Ping Bu; Shivanee Shah; Liang Qiao
Journal:  Nat Commun       Date:  2017-04-11       Impact factor: 14.919

Review 7.  Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection.

Authors:  Chongbo Zhao; Zhujun Ao; Xiaojian Yao
Journal:  Vaccines (Basel)       Date:  2016-01-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.